江蘇吳中(600200.SH)姚建林出讓控股股東10%股權予杭州復暉實業有限公司
格隆匯8月15日丨江蘇吳中(600200.SH)公佈,公司於2019年8月15日收到控股股東吳中投資通知:
姚建林將其持有的吳中投資10%的股權轉讓給杭州復暉實業有限公司。轉讓後,姚建林仍持有吳中投資5.1515%的股權,杭州復暉實業有限公司持有吳中投資的股權比例從60.6061%增加到70.6061%。
黃連堅將其持有的浙江復基控股集團有限公司5%的股權轉讓給錢羣山。
本次變更後,公司的控股股東和實際控制人都未發生變化,公司控股股東仍為蘇州吳中投資控股有限公司,公司實際控制人仍為錢羣英。本次股權變更不會導致公司主要業務結構發生變化,對公司經營活動不構成影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.